{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclin-Dependent+Kinase+4+Inhibitor&page=3", "query": { "intervention": "Cyclin-Dependent Kinase 4 Inhibitor", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclin-Dependent+Kinase+4+Inhibitor&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclin-Dependent+Kinase+4+Inhibitor&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T08:00:40.620Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01536743", "title": "A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Epithelial Carcinoma" ], "interventions": [ { "name": "PD0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2011-12-15", "completion_date": "2020-02-24", "has_results": false, "last_update_posted_date": "2020-06-05", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01536743" }, { "nct_id": "NCT07222267", "title": "An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-75202", "type": "DRUG" }, { "name": "CDK4 Inhibitor", "type": "DRUG" }, { "name": "Estrogen Receptor Antagonist", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2025-12-11", "completion_date": "2037-01-13", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 6, "location_summary": "Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222267" }, { "nct_id": "NCT00446342", "title": "Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-lymphoid Malignancies", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "SNS-032 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunesis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2007-02", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 6, "location_summary": "Duarte, California • Stanford, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00446342" }, { "nct_id": "NCT05361655", "title": "Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib + an aromatase inhibitor", "type": "DRUG" }, { "name": "Aromatase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2888, "start_date": "2021-09-01", "completion_date": "2021-09-01", "has_results": true, "last_update_posted_date": "2024-06-07", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05361655" }, { "nct_id": "NCT03056755", "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2017-08-29", "completion_date": "2024-11-12", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056755" }, { "nct_id": "NCT05935748", "title": "Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ccRCC", "Clear Cell Renal Cell Carcinoma", "Kidney Cancer", "Kidney Neoplasms", "Renal Cancer", "Renal Neoplasms", "Recurrent Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Refractory Renal Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Carcinoma", "Neoplasms", "Carcinoma, Renal Cell", "Neoplasms, Glandular and Epithelial", "Neoplasm by Histology", "Adenocarcinoma", "Urologic Neoplasms", "Urogenital Neoplasms", "Neoplasms by Site", "Kidney Diseases", "Urologic Diseases" ], "interventions": [ { "name": "NKT2152", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "sasanlimab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-07-28", "completion_date": "2025-09-04", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 8, "location_summary": "La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05935748" }, { "nct_id": "NCT02503709", "title": "Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "CDK Inhibitor AT7519", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Onalespib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-09-30", "completion_date": "2020-10-09", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02503709" }, { "nct_id": "NCT03285412", "title": "CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2017-12-12", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Danvers, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Danvers", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03285412" }, { "nct_id": "NCT07191717", "title": "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Localized Estrogen Receptor-Positive Breast Carcinoma", "Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-05-18", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07191717" }, { "nct_id": "NCT01026324", "title": "Dinaciclib in Treating Patients With Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "dinaciclib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-09", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-08T08:00:40.620Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026324" } ] }